PIRS Pieris Pharmaceuticals Inc.

2.92
-0.14  -5%
Previous Close 3.06
Open 3.05
Price To Book 3.14
Market Cap 158117179
Shares 54,149,719
Volume 564,516
Short Ratio
Av. Daily Volume 547,092

SEC filingsSee all SEC filings

  1. 8-K - Current report 181191277
  2. 8-K - Current report 181186067
  3. 8-K - Current report 181172108
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166265
  5. 8-K - Current report 181164710

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 1H 2019.
PRS-080
Anemia of chronic disease
Phase 1 initial data due at upcoming meeting.
PRS-060
Healthy subjects
Phase 1 data due 1H 2019.
PRS-343
HER2-positive solid tumors
Phase 1 data due 2019.
PRS-343 and atezolizumab (Tecentriq)
HER2-positive solid tumors

Latest News

  1. How Much Did Pieris Pharmaceuticals Inc’s (NASDAQ:PIRS) CEO Pocket Last Year?
  2. New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
  3. Edited Transcript of PIRS earnings conference call or presentation 7-Nov-18 1:00pm GMT
  4. P.A.W. Capital Partners’ Returns, AUM, and Holdings
  5. Pieris Pharmaceuticals to Present at Investor Conferences in November
  6. Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
  7. Pieris Pharmaceuticals: 3Q Earnings Snapshot
  8. Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  9. Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018
  10. Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors
  11. Are Pieris Pharmaceuticals Inc’s (NASDAQ:PIRS) Interest Costs Too High?
  12. New Research Coverage Highlights Dorian LPG, Avadel Pharmaceuticals, Pieris Pharmaceuticals, Resolute Energy, American Public Education, and THL Credit — Consolidated Revenues, Company Growth, and Expectations for 2018
  13. Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
  14. Pieris Pharmaceuticals to Present at Investor Conferences in October
  15. Edited Transcript of PIRS earnings conference call or presentation 9-Aug-18 12:00pm GMT

SEC Filings

  1. 8-K - Current report 181191277
  2. 8-K - Current report 181186067
  3. 8-K - Current report 181172108
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166265
  5. 8-K - Current report 181164710
  6. 8-K - Current report 181147371
  7. 8-K - Current report 181137717
  8. 8-K - Current report 181099555
  9. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181091443
  10. 8-K - Current report 181077127